Posts Archive

July 24, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the...

A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly...

HORSHAM, PA, November 16, 2015 – Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today the U.S....

SUMMIT, N.J., February 18, 2015 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug...

Myeloma Canada: Patient Handbook - Understanding Your Blood and Blood Tests https://myeloma.ca/pixms/uploads/serve/ckeditor/understanding...

Myeloma UK - Myeloma Animations Clonal evolution: the changing nature of myeloma Learn More: https://www.myeloma.org.uk/

NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma A Phase 1 Study in Subjects With Relapsed or...

NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas,...

April 23, 2015; SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it has fulfilled the accelerated...

MMY1004 (PAVO) Study RRMM The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and...

NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma Open-label, single-center, pilot study to assess the safety and feasibility...

EMN12/HOVON129 Study Phase 2: To evaluate progression-free survival in adult pPCL patients by incorporation of carfilzomib and...

Phase 3 A.R.R.O.W. trial - ARROW Kd The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib...

GEM14 Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM Trial Studying...

An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...

MMY3003 (POLLUX) Study NCT02076009: Phase 3: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and...

Myeloma UK - Myeloma Animations High Dose Therapy and Autologous Stem Cell Transplantation Learn More: https://www.myeloma.org.uk/

Charlotte Radiology: Port Placement: Dr. Eric Wang

IFM2014-02 NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With...

NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple...

DREAMM-1 study Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity...

Myeloma UK - Myeloma Animations Myeloma Kidney Disease Learn More: https://www.myeloma.org.uk/

NCT02046070: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients...